Northern Trust
ARTV

Northern Trust’s Artiva Biotherapeutics ARTV Stock Holding History

Northern Trust’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$741K Buy
76,423
+64,215
+526% +$585K ﹤0.01% 3566
2026
Q1 		$78.6K Buy
+12,208
New +$60.4K ﹤0.01% 4158
2025
Q3 		– Sell
-34,964
Closed -$52.8K – 4555
2025
Q2 		$52.8K Sell
34,964
-106,712
-75% -$224K ﹤0.01% 4223
2025
Q1 		$425K Buy
141,676
+24,564
+21% +$133K ﹤0.01% 3637
2024
Q4 		$1.18M Buy
117,112
+4,335
+4% +$52.1K ﹤0.01% 3316
2024
Q3 		$1.74M Buy
+112,777
New +$1.31M ﹤0.01% 3085

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Northern Trust's ARTV Position: Q2 2026 in Review

Northern Trust increased its Artiva Biotherapeutics (ARTV) stake by 526% in Q2 2026, buying an estimated $585K and bringing the position to 76,423 shares worth $741K. The position accounts for ﹤0.01% of the portfolio, ranked #3566.

Northern Trust first reported a position in ARTV in Q3 2024 and has held it in 6 quarters since. The position peaked at $1.74M in Q3 2024. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Northern Trust held 76,423 shares of Artiva Biotherapeutics worth $741K as of Q2 2026.
  • Northern Trust bought 64,215 Artiva Biotherapeutics shares in Q2 2026, an estimated $585K.
  • Artiva Biotherapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3566 holding.
  • Northern Trust first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 6 quarters since.
  • Northern Trust's Artiva Biotherapeutics position peaked at $1.74M in Q3 2024.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.